Cognitive-Adaptive Disabilities

Pediatric Clinics of North America

Volumn 58, Issue 1, 2011, Pages 189-203

  Calles, Joseph L ^a,b  

^a Michigan State University   (United States)

^b Michigan State University Kalamazoo Center for Medical Studies   (United States)

Author keywords

Cognitive adaptive disabilities; Developmental disorders; Epidemiology; Pharmacologic treatment

Indexed keywords

AMFEBUTAMONE; ANTICONVULSIVE AGENT; ARIPIPRAZOLE; ATOMOXETINE; BUSPIRONE; CITALOPRAM; CLONIDINE; DEXAMPHETAMINE; DONEPEZIL; DULOXETINE; FLUOXETINE; GUANFACINE; METHYLPHENIDATE; OLANZAPINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

AGGRESSION; AGITATION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; BIPOLAR DISORDER; BIPOLAR I DISORDER; CLINICAL FEATURE; COGNITIVE ADAPTIVE DISABILITY; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSKINESIA; EVIDENCE BASED MEDICINE; FETAL ALCOHOL SYNDROME; FRAGILE X SYNDROME; HUMAN; LOW DRUG DOSE; NEUROFIBROMATOSIS; OBSESSIVE COMPULSIVE DISORDER; PREVALENCE; PSYCHOLOGIC ASSESSMENT; PSYCHOPHARMACOLOGY; PSYCHOSIS; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; TUBEROUS SCLEROSIS; UNSPECIFIED SIDE EFFECT; VELOCARDIOFACIAL SYNDROME;

ADOLESCENT; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; COGNITION DISORDERS; COMORBIDITY; DEVELOPMENTAL DISABILITIES; DIGEORGE SYNDROME; DOWN SYNDROME; FEMALE; FETAL ALCOHOL SYNDROME; FRAGILE X SYNDROME; HUMANS; MALE; NEUROFIBROMATOSIS 1; PREGNANCY; TUBEROUS SCLEROSIS;

EID: 79251574673     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2010.10.003     Document Type: Review

References (66)

1. Shevell M., Ashwal S., Donley D., et al. Practice parameter: evaluation of the child with global developmental delay: report of the Quality Standards Subcommittee of the American Academy of Neurology and The Practice Committee of the Child Neurology Society. Neurology 2003, 60:367-380.
2. Leonard H., Wen X. The epidemiology of mental retardation: challenges and opportunities in the new millennium. Ment Retard Dev Disabil Res Rev 2002, 8(3):117-134.
3. Centers for Disease Control and Prevention Prevalence of autism spectrum disorders. Autism and Developmental Disabilities Monitoring Network, United States, 2006. MMWR Surveill Summ 2009, 58(No. SS-10):1-20.
4. Matson J.L., Shoemaker M. Intellectual disability and its relationship to autism spectrum disorders. Res Dev Disabil 2009, 30(6):1107-1114.
5. Emerson E. Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. J Intellect Disabil Res 2003, 47(Pt 1):51-58.
6. Einfeld S.L., Piccinin A.M., Mackinnon A., et al. Psychopathology in young people with intellectual disability. JAMA 2006, 296(16):1981-1989.
7. de Ruiter K.P., Dekker M.C., Verhulst F.C., et al. Developmental course of psychopathology in youths with and without intellectual disabilities. J Child Psychol Psychiatry 2007, 48(5):498-507.
8. Shin M., Besser L.M., Kucik J.E., et al. Prevalence of Down syndrome among children and adolescents in 10 regions of the United States. Pediatrics 2009, 124(6):1565-1571.
9. Myers B.A., Pueschel S.M. Psychiatric disorders in persons with Down syndrome. J Nerv Ment Dis 1991, 179(10):609-613.
10. Craddock N., Owen M. Is there an inverse relationship between Down's syndrome and bipolar affective disorder? Literature review and genetic implications. J Intellect Disabil Res 1994, 38(6):613-620.
11. Prasher V.P., Day S. Brief report: obsessive-compulsive disorder in adults with Down's syndrome. J Autism Dev Disord 1995, 25:453-458.
12. Evans D.W., Gray F.L. Compulsive-like behavior in individuals with Down syndrome: its relation to mental age level, adaptive and maladaptive behavior. Child Dev 2000, 71(2):288-300.
13. Hurley A.D. Delusions and hallucinations in Down syndrome: literature review and comparison with non-down syndrome patients. Ment Health Aspect Dev Disabil 2003, 6(4):135-146.
14. Nieuwenhuis-Mark R.E. Diagnosing Alzheimer's dementia in Down syndrome: problems and possible solutions. Res Dev Disabil 2009, 30(5):827-838.
15. Dierssen M., Ortiz-Abalia J., Arque G., et al. Pitfalls and hopes in Down syndrome therapeutic approaches: in the search for evidence-based treatments. Behav Genet 2006, 36(3):454-468.
16. Sutor B., Hansen M.R., Black J.L. Obsessive compulsive disorder treatment in patients with Down syndrome: a case series. Downs Syndr Res Pract 2006, 10(1):1-3.
17. Huang H., Ruedrich S. Recent advances in the diagnosis and treatment of attention-deficit/hyperactivity disorder in individuals with intellectual disability. Ment Health Aspect Dev Disabil 2007, 10(4):121-128.
18. Friedlander R., Lazar S., Klancnik J. Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Can J Psychiatry 2001, 46:741-745.
19. Prasher V.P. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population. Int J Geriatr Psychiatry 2004, 19(6):509-515.
20. Coffee B., Keith K., Albizua I., et al. Incidence of fragile X syndrome by newborn screening for methylated FMR1 DNA. Am J Hum Genet 2009, 85(4):503-514.
21. Hunter J.E., Allen E.G., Abramowitz A., et al. Investigation of phenotypes associated with mood and anxiety among male and female fragile X premutation carriers. Behav Genet 2008, 38(5):493-502.
22. Freund L.S., Reiss A.L., Abrams M.T. Psychiatric disorders associated with fragile X in the young female. Pediatrics 1993, 91(2):321-329.
23. Hessl D., Dyer-Friedman J., Glaser B., et al. The influence of environmental and genetic factors on behavior problems and autistic symptoms in boys and girls with fragile X syndrome. Pediatrics 2001, 108(5):E88.
24. Sullivan K., Hooper S., Hatton D. Behavioural equivalents of anxiety in children with fragile X syndrome: parent and teacher report. J Intellect Disabil Res 2007, 51(1):54-65.
25. Sullivan K., Hatton D., Hammer J., et al. ADHD symptoms in children with FXS. Am J Med Genet A 2006, 140(21):2275-2288.
26. Backes M., Genç B., Schreck J., et al. Cognitive and behavioral profile of fragile X boys: correlations to molecular data. Am J Med Genet 2000, 95(2):150-156.
27. Berry-Kravis E., Potanos K. Psychopharmacology in fragile X syndrome: present and future. Ment Retard Dev Disabil Res Rev 2004, 10(1):42-48.
28. Hagerman R.J., Berry-Kravis E., Kaufmann W.E., et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009, 123(1):378-390.
29. May P.A., Gossage J.P., Kalberg W.O., et al. Prevalence and epidemiologic characteristics of FASD from various research methods with an emphasis on recent in-school studies. Dev Disabil Res Rev 2009, 15(3):176-192.
30. O'Connor M.J., Shah B., Whaley S., et al. Psychiatric illness in a clinical sample of children with prenatal alcohol exposure. Am J Drug Alcohol Abuse 2002, 28(4):743-754.
31. Bhatara V., Loudenberg R., Ellis R. Association of attention deficit hyperactivity disorder and gestational alcohol exposure: an exploratory study. J Atten Disord 2006, 9(3):515-522.
32. Roebuck T.M., Mattson S.N., Riley E.P. Behavioral and psychosocial profiles of alcohol-exposed children. Alcohol Clin Exp Res 1999, 23(6):1070-1076.
33. Schonfeld A.M., Mattson S.N., Riley E.P. Moral maturity and delinquency after prenatal alcohol exposure. J Stud Alcohol 2005, 66(4):545-554.
34. Burd L., Klug M.G., Martsolf J.T., et al. Fetal alcohol syndrome: neuropsychiatric phenomics. Neurotoxicol Teratol 2003, 25(6):697-705.
35. Hamrin V., Iennaco J.D. Psychopharmacology of pediatric bipolar disorder. Expert Rev Neurother 2010, 10(7):1053-1088.
36. Hagerman R.J. Psychopharmacological interventions in fragile X syndrome, fetal alcohol syndrome, Prader-Willi syndrome, Angelman syndrome, Smith-Magenis syndrome, and velocardiofacial syndrome. Ment Retard Dev Disabil Res Rev 1999, 5:305-313.
37. Doig J., McLennan J.D., Gibbard W.B. Medication effects on symptoms of attention-deficit/hyperactivity disorder in children with fetal alcohol spectrum disorder. J Child Adolesc Psychopharmacol 2008, 18(4):365-371.
38. Herbert M.R. Contributions of the environment and environmentally vulnerable physiology to autism spectrum disorders. Curr Opin Neurol 2010, 23(2):103-110.
39. Kim J.A., Szatmari P., Bryson S.E., et al. The prevalence of anxiety and mood problems among children with autism and Asperger syndrome. Autism 2000, 4(2):117-132.
40. Stewart M.E., Barnard L., Pearson J., et al. Presentation of depression in autism and Asperger syndrome: a review. Autism 2006, 10(1):103-116.
41. Munesue T., Ono Y., Mutoh K., et al. High prevalence of bipolar disorder comorbidity in adolescents and young adults with high-functioning autism spectrum disorder: a preliminary study of 44 outpatients. J Affect Disord 2008, 111(2-3):170-175.
42. Sukhodolsky D.G., Scahill L., Gadow K.D., et al. Parent-rated anxiety symptoms in children with pervasive developmental disorders: frequency and association with core autism symptoms and cognitive functioning. J Abnorm Child Psychol 2008, 36(1):117-128.
43. Rommelse N.N., Franke B., Geurts H.M., et al. Shared heritability of attention-deficit/hyperactivity disorder and autism spectrum disorder. Eur Child Adolesc Psychiatry 2010, 19(3):281-295.
44. Xue M., Brimacombe M., Chaaban J., et al. Autism spectrum disorders: concurrent clinical disorders. J Child Neurol 2008, 23(1):6-13.
45. Lecavalier L. Behavior and emotional problems in young people with pervasive developmental disorders: relative prevalence, effects of subject characteristics, and empirical classification. J Autism Dev Disord 2006, 36(8):1101-1114.
46. Matson J.L., Wilkins J., Macken J. The relationship of challenging behaviors to severity and symptoms of autism spectrum disorders. J Ment Health Res Intellect Disabil 2009, 2(1):29-44.
47. Williams K., Wheeler D.M., Silove N., et al. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 2010, 8. CD004677.
48. Hamrin V., McDonnell M.A., Moffett J., et al. Psychopharmacological treatment of non-comorbid and comorbid pervasive developmental disorder and pediatric bipolar disorder. Minerva Pediatr 2008, 60(1):87-101.
49. Blankenship K., Erickson C.A., McDougle C.J. Pharmacotherapy of autism and related disorders. Psychiatr Ann 2010, 40(4):203-209.
50. Rasmussen S.A., Friedman J.M. NF1 gene and neurofibromatosis 1. Am J Epidemiol 2000, 151(1):33-40.
51. Johnson N.S., Saal H.M., Lovell A.M., et al. Social and emotional problems in children with neurofibromatosis type 1: evidence and proposed interventions. J Pediatr 1999, 134(6):767-772.
52. Noll R.B., Reiter-Purtill J., Moore B.D., et al. Social, emotional, and behavioral functioning of children with NF1. Am J Med Genet A 2007, 143(19):2261-2273.
53. Mautner V.F., Kluwe L., Thakker S.D., et al. Treatment of ADHD in neurofibromatosis type 1. Dev Med Child Neurol 2002, 44(3):164-170.
54. Botto L.D., May K., Fernhoff P.M., et al. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics 2003, 112(1):101-117.
55. Antshel K.M., Fremont W., Roizen N.J., et al. ADHD, major depressive disorder, and simple phobias are prevalent psychiatric conditions in youth with velocardiofacial syndrome. J Am Acad Child Adolesc Psychiatry 2006, 45(5):596-603.
56. Carlson C., Papolos D., Pandita R.K., et al. Molecular analysis of velo-cardio-facial syndrome patients with psychiatric disorders. Am J Hum Genet 1997, 60(4):851-859.
57. Gothelf D., Presburger G., Zohar A.H., et al. Obsessive-compulsive disorder in patients with velocardiofacial (22q11 deletion) syndrome. Am J Med Genet B Neuropsychiatr Genet 2004, 126(1):99-105.
58. Murphy K.C. Annotation: velo-cardio-facial syndrome. J Child Psychol Psychiatry 2005, 46(6):563-571.
59. Stoddard J., Niendam T., Hendren R., et al. Attenuated positive symptoms of psychosis in adolescents with chromosome 22q11.2 deletion syndrome. Schizophr Res 2010, 118(1-3):118-121.
60. Gothelf D., Gruber R., Presburger G., et al. Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. J Clin Psychiatry 2003, 64(10):1163-1169.
61. Kao A., Mariani J., McDonald-McGinn D.M., et al. Increased prevalence of unprovoked seizures in patients with a 22q11.2 deletion. Am J Med Genet 2004, 129:29-34.
62. Morrison P.J. Tuberous sclerosis: epidemiology, genetics and progress towards treatment. Neuroepidemiology 2009, 33(4):342-343.
63. de Vries P.J., Hunt A., Bolton P.F. The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families. Eur Child Adolesc Psychiatry 2007, 16(1):16-24.
64. Muzykewicz D.A., Newberry P., Danforth N., et al. Psychiatric comorbid conditions in a clinic population of 241 patients with tuberous sclerosis complex. Epilepsy Behav 2007, 11(4):506-513.
65. Asato M.R., Hardan A.Y. Neuropsychiatric problems in tuberous sclerosis complex. J Child Neurol 2004, 19(4):241-249.
66. D'Agati E., Moavero R., Cerminara C., et al. Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex. J Child Neurol 2009, 24(10):1282-1287.